Posted by Michael Wonder on 15 Aug 2024
Accutar Biotechnology receives FDA fast track designation for AC699 in ER positive, HER2 negative breast cancer
14 August 2024 - Accutar Biotechnology announced today that the US FDA has granted the investigation of AC699 a fast track designation for the treatment of patients with oestrogen receptor positive, human epidermal growth factor receptor 2 negative, oestrogen receptor 1 mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.
AC699 is an investigational orally bioavailable, chimeric degrader of oestrogen receptor α currently in a Phase 1 trial.
